卡伯戈林在患有前性瘤的青少年中诱导了病态博
Ummahan Tercan1, Ezgi Sarban1, Melek Yildiz1
1Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Journal of clinical research in pediatric endocrinology
|January 24, 2025
概括
在青少年中,多巴胺激动剂治疗益生菌瘤可能会导致罕见的副作用,如病态博. 在卡伯戈林治疗期间,仔细的精神病监测至关重要.
科学领域:
- 神经内分泌学神经内分泌学
- 儿科内分泌学 儿科内分泌学
- 精神病学是一个精神病学.
背景情况:
- 甲状腺瘤是青少年常见的垂体瘤.
- 多巴胺激动剂 (DA) 是主要的治疗方法.
- 虽然身体副作用是已知的,但像病态博 (PG) 这样的冲动控制障碍 (ICD) 在成年人中被报告.
研究的目的:
- 报告第一个病理性博 (PG) 病例,该病例发生在一名青少年身上,该青少年因前素分泌 pituitary macroadenoma而接受卡贝戈林 (CBG) 治疗.
- 突出DA治疗在儿科患者的潜在精神病学副作用.
主要方法:
- 一名15.7岁的男性被诊断出患有前素分泌 pituitary macroadenoma 的病例报告.
- 开始使用卡伯戈林 (CBG) 的治疗.
- 监测益乳素水平,瘤大小和精神症状,包括CBG剂量调整后PG的发展和停止.
主要成果:
- 卡伯戈林 (CBG) 能使益生菌水平正常化,并减少瘤大小.
- 患者在接受CBG治疗2.5年后 (每周1.5毫克) 发展出病态博 (PG).
- 在降低CBG剂量后,PG症状消失了.
结论:
- 这是第一个报告的PG作为cabergoline (CBG) 的副作用的案例,该病例发生在患有前乳腺瘤的青少年身上.
- 强调需要对接受多巴胺激动剂 (DA) 的儿科患者进行警的精神监测.
- 这表明CBG和青少年的ICD之间存在潜在的联系,需要进一步调查.
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview
306
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
306


